Restricted accessResearch articleFirst published online 2018-03
Human Umbilical Cord Perivascular Cells and Human Bone Marrow Mesenchymal Stromal Cells Transplanted Intramuscularly Respond to a Distant Source of Inflammation
Intravenously administered mesenchymal stromal cells (MSCs) are rapidly entrapped in the lungs, where they display an anti-inflammatory phenotype. Intramuscular (IM) delivery provides an increased MSC dwell-time, which could result in a sustained modulation of an inflammatory milieu. We studied the therapeutic effects of IM delivered MSCs to treat a distant (contralateral) inflammation, and compared the efficacy of neonatal (umbilical cord) and adult bone marrow MSCs (BMMSCs). Inflammation decreased over 48 h, but neonatal cells showed an earlier response than BMMSCs. Tumor necrosis factor-induced gene-6 (TSG-6) was released at the site of MSC delivery, while neutrophil infiltration was abrogated and inflammation reduced at the contralateral site. MSCs did not distribute to the organs or to the site of inflammation. Thus, IM delivery presents a promising alternative for the treatment of inflammation, and neonatal MSCs may represent a stronger candidate than those derived from adult BM to treat inflammatory diseases.
Get full access to this article
View all access options for this article.
References
1.
BarbashIM, ChouraquiP, BaronJ, FeinbergMS, EtzionS, TessoneA, MillerL, GuettaE, ZiporiD, et al. (2003). Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium: feasibility, cell migration, and body distribution. Circulation, 108:863–868.
2.
LeeRH, PulinAA, SeoMJ, KotaDJ, YlostaloJ, LarsonBL, Semprun-PrietoL, DelafontaineP and ProckopDJ. (2009). Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell, 5:54–63.
3.
KiernanJ, HuS, GrynpasMD, DaviesJE and StanfordWL. (2016). Systemic mesenchymal stromal cell transplantation prevents functional bone loss in a mouse model of age-related osteoporosis. Stem Cells Transl Med, 5:683–693.
4.
LeeJS, HongJM, MoonGJ, LeePH, AhnYH and BangOY. (2010). A long-term follow-up study of intravenous autologous mesenchymal stem cell transplantation in patients with ischemic stroke. Stem Cells, 28:1099–1106.
5.
ChullikanaA, MajumdarAS, GottipamulaS, KrishnamurthyS, KumarAS, PrakashVS and GuptaPK. (2015). Randomized, double-blind, phase I/II study of intravenous allogeneic mesenchymal stromal cells in acute myocardial infarction. Cytotherapy, 17:250–261.
6.
BraidLR, WoodCA, WieseDM and FordBN. (2018). Intramuscular administration potentiates extended dwell time of mesenchymal stromal cells compared to other routes. Cytotherapy, 20:232–244.
7.
BartholomewA, PatilS, MackayA, NelsonM, BuyanerD, HardyW, MoscaJ, SturgeonC, SiatskasM, MahmudN, et al. (2001). Baboon mesenchymal stem cells can be genetically modified to secrete human erythropoietin in vivo. Hum Gene Ther, 12:1527–1541.
8.
VilaltaM, DeganoIR, BagoJ, GouldD, SantosM, Garcia-ArranzM, AyatsR, FusterC, ChernajovskyY, et al. (2008). Biodistribution, long-term survival, and safety of human adipose tissue-derived mesenchymal stem cells transplanted in nude mice by high sensitivity non-invasive bioluminescence imaging. Stem Cells Dev, 17:993–1003.
RamotY, MeironM, TorenA, SteinerM and NyskaA. (2009). Safety and biodistribution profile of placental-derived mesenchymal stromal cells (PLX-PAD) following intramuscular delivery. Toxicol Pathol, 37:606–616.
11.
CreaneM, HowardL, O'BrienT and ColemanCM. (2017). Biodistribution and retention of locally administered human mesenchymal stromal cells: quantitative polymerase chain reaction-based detection of human DNA in murine organs. Cytotherapy, 19:384–394.
12.
GaoJ, DennisJE, MuzicRF, LundbergM and CaplanAI. (2001). The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. Cells Tissues Organs, 169:12–20.
13.
FischerUM, HartingMT, JimenezF, Monzon-PosadasWO, XueH, SavitzSI, LaineGA and CoxCSJr. (2009). Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect. Stem Cells Dev, 18:683–692.
14.
KeanTJ, LinP, CaplanAI and DennisJE. (2013). MSCs: delivery routes and engraftment, cell-targeting strategies, and immune modulation. Stem Cells Int, 2013:732742.
15.
LeibacherJ and HenschlerR. (2016). Biodistribution, migration and homing of systemically applied mesenchymal stem/stromal cells. Stem Cell Res Ther, 7:7.
16.
ShabbirA, ZisaD, LeikerM, JohnstonC, LinH and LeeT. (2009). Muscular dystrophy therapy by nonautologous mesenchymal stem cells: muscle regeneration without immunosuppression and inflammation. Transplantation, 87:1275–1282.
17.
ShabbirA, ZisaD, SuzukiG and LeeT. (2009). Heart failure therapy mediated by the trophic activities of bone marrow mesenchymal stem cells: a noninvasive therapeutic regimen. Am J Physiol Heart Circ Physiol, 296:H1888–H1897.
18.
ZisaD, ShabbirA, MastriM, SuzukiG and LeeT. (2009). Intramuscular VEGF repairs the failing heart: role of host-derived growth factors and mobilization of progenitor cells. Am J Physiol Regul Integr Comp Physiol, 297:R1503–R1515.
19.
MaoC, HouX, WangB, ChiJ, JiangY, ZhangC and LiZ. (2017). Intramuscular injection of human umbilical cord-derived mesenchymal stem cells improves cardiac function in dilated cardiomyopathy rats. Stem Cell Res Ther, 8:18.
20.
NagayaN, KangawaK, ItohT, IwaseT, MurakamiS, MiyaharaY, FujiiT, UematsuM, OhgushiH, et al. (2005). Transplantation of mesenchymal stem cells improves cardiac function in a rat model of dilated cardiomyopathy. Circulation, 112:1128–1135.
21.
WangD, ZhangF, ShenW, ChenM, YangB, ZhangY and CaoK. (2011). Mesenchymal stem cell injection ameliorates the inducibility of ventricular arrhythmias after myocardial infarction in rats. Int J Cardiol, 152:314–320.
22.
WangP, ZhangY, ZhaoJ and JiangB. (2015). Intramuscular injection of bone marrow mesenchymal stem cells with small gap neurorrhaphy for peripheral nerve repair. Neurosci Lett, 585:119–125.
23.
ConsentiusC, AkyuzL, Schmidt-LuckeJA, TschopeC, PinzurL, OfirR, ReinkeP, VolkHD and JuelkeK. (2015). Mesenchymal stromal cells prevent allostimulation in vivo and control checkpoints of Th1 priming: migration of human DC to lymph nodes and NK cell activation. Stem Cells, 33:3087–3099.
24.
LiuLN, WangG, HendricksK, LeeK, BohnleinE, JunkerU and MoscaJD. (2013). Comparison of drug and cell-based delivery: engineered adult mesenchymal stem cells expressing soluble tumor necrosis factor receptor II prevent arthritis in mouse and rat animal models. Stem Cells Transl Med, 2:362–375.
25.
MorrisCJ. (2003). Carrageenan-induced paw edema in the rat and mouse. Methods Mol Biol, 225:115–121.
26.
WurdingerT, BadrC, PikeL, de KleineR, WeisslederR, BreakefieldXO and TannousBA. (2008). A secreted luciferase for ex vivo monitoring of in vivo processes. Nat Methods, 5:171–173.
27.
TannousBA. (2009). Gaussia luciferase reporter assay for monitoring biological processes in culture and in vivo. Nat Protoc, 4:582–591.
28.
El-AmouriSS, CaoP, MiaoC and PanD. (2013). Secreted luciferase for in vivo evaluation of systemic protein delivery in mice. Mol Biotechnol, 53:63–73.
29.
ElmanJS, MurrayRC, WangF, ShenK, GaoS, ConwayKE, YarmushML, TannousBA, WeisslederR and ParekkadanB. (2014). Pharmacokinetics of natural and engineered secreted factors delivered by mesenchymal stromal cells. PLoS One, 9:e89882.
30.
PosadasI, BucciM, RoviezzoF, RossiA, ParenteL, SautebinL and CirinoG. (2004). Carrageenan-induced mouse paw oedema is biphasic, age-weight dependent and displays differential nitric oxide cyclooxygenase-2 expression. Br J Pharmacol, 142:331–338.
31.
MaguireCA, DeliolanisNC, PikeL, NiersJM, Tjon-Kon-FatLA, Sena-EstevesM and TannousBA. (2009). Gaussia luciferase variant for high-throughput functional screening applications. Anal Chem, 81:7102–7106.
32.
ShimomuraO, KishiY and InouyeS. (1993). The relative rate of aequorin regeneration from apoaequorin and coelenterazine analogues. Biochem J, 296,(Pt 3)::549–551.
33.
ZhaoH, DoyleTC, WongRJ, CaoY, StevensonDK, Piwnica-WormsD and ContagCH. (2004). Characterization of coelenterazine analogs for measurements of Renilla luciferase activity in live cells and living animals. Mol Imaging, 3:43–54.
34.
Hamidian JahromiS, LiY and DaviesJE. (2018). Effect of tumor necrosis factor alpha dose and exposure time on tumor necrosis factor-induced gene-6 activation by neonatal and adult mesenchymal stromal cells. Stem Cells Dev, 27:44–54.
35.
MatobaS, TatsumiT, MuroharaT, ImaizumiT, KatsudaY, ItoM, SaitoY, UemuraS, SuzukiH, et al. (2008). Long-term clinical outcome after intramuscular implantation of bone marrow mononuclear cells (Therapeutic Angiogenesis by Cell Transplantation [TACT] trial) in patients with chronic limb ischemia. Am Heart J, 156:1010–1018.
36.
WesterT, JorgensenJJ, StrandenE, SandbaekG, TjonnfjordG, BayD, KollerosD, KroeseAJ and BrinchmannJE. (2008). Treatment with autologous bone marrow mononuclear cells in patients with critical lower limb ischaemia. A pilot study. Scand J Surg, 97:56–62.
37.
GuptaPK, ChullikanaA, ParakhR, DesaiS, DasA, GottipamulaS, KrishnamurthyS, AnthonyN, PherwaniA and MajumdarAS. (2013). A double blind randomized placebo controlled phase I/II study assessing the safety and efficacy of allogeneic bone marrow derived mesenchymal stem cell in critical limb ischemia. J Transl Med, 11:143.
38.
LaurilaJP, LaatikainenL, CastelloneMD, TrivediP, HeikkilaJ, HinkkanenA, HemattiP and LaukkanenMO. (2009). Human embryonic stem cell-derived mesenchymal stromal cell transplantation in a rat hind limb injury model. Cytotherapy, 11:726–737.
39.
Gaby RitfeldMO. (2014). Bone marrow-derived mesenchymal stem cell transplant survival in the injured rodent spinal cord. J Bone Marrow Res, 2:146.
40.
LeeS, ChoiE, ChaMJ and HwangKC. (2015). Cell adhesion and long-term survival of transplanted mesenchymal stem cells: a prerequisite for cell therapy. Oxid Med Cell Longev, 2015:632902.
41.
SingerNG and CaplanAI. (2011). Mesenchymal stem cells: mechanisms of inflammation. Annu Rev Pathol, 6:457–478.
KolaczkowskaE and KubesP. (2013). Neutrophil recruitment and function in health and inflammation. Nat Rev Immunol, 13:159–175.
44.
OhJY, RoddyGW, ChoiH, LeeRH, YlostaloJH, RosaRHJr and ProckopDJ. (2010). Anti-inflammatory protein TSG-6 reduces inflammatory damage to the cornea following chemical and mechanical injury. Proc Natl Acad Sci U S A, 107:16875–16880.
45.
DyerDP, SalangaCL, JohnsSC, ValdambriniE, FusterMM, MilnerCM, DayAJ and HandelTM. (2016). The anti-inflammatory protein TSG-6 regulates chemokine function by inhibiting chemokine/glycosaminoglycan interactions. J Biol Chem, 291:12627–12640.
46.
ChoiH, LeeRH, BazhanovN, OhJY and ProckopDJ. (2011). Anti-inflammatory protein TSG-6 secreted by activated MSCs attenuates zymosan-induced mouse peritonitis by decreasing TLR2/NF-kappaB signaling in resident macrophages. Blood, 118:330–338.
47.
HassR, KasperC, BohmS and JacobsR. (2011). Different populations and sources of human mesenchymal stem cells (MSC): a comparison of adult and neonatal tissue-derived MSC. Cell Commun Signal, 9:12.
48.
HuL, HuJ, ZhaoJ, LiuJ, OuyangW, YangC, GongN, DuL, KhanalA and ChenL. (2013). Side-by-side comparison of the biological characteristics of human umbilical cord and adipose tissue-derived mesenchymal stem cells. BioMed Res Int, 2013:438243.
49.
DabrowskiFA, BurdzinskaA, KuleszaA, SladowskaA, ZolocinskaA, GalaK, PaczekL and WielgosM. (2017). Comparison of the paracrine activity of mesenchymal stem cells derived from human umbilical cord, amniotic membrane and adipose tissue. J Obstet Gynaecol Res, 43:1758–1768.
50.
RaicevicG, NajarM, StamatopoulosB, De BruynC, MeulemanN, BronD, ToungouzM and LagneauxL. (2011). The source of human mesenchymal stromal cells influences their TLR profile as well as their functional properties. Cell Immunol, 270:207–216.
51.
BarlowS, BrookeG, ChatterjeeK, PriceG, PelekanosR, RossettiT, DoodyM, VenterD, PainS, GilshenanK and AtkinsonK. (2008). Comparison of human placenta- and bone marrow-derived multipotent mesenchymal stem cells. Stem Cells Dev, 17:1095–1107.
52.
ZhouC, YangB, TianY, JiaoH, ZhengW, WangJ and GuanF. (2011). Immunomodulatory effect of human umbilical cord Wharton's jelly-derived mesenchymal stem cells on lymphocytes. Cell Immunol, 272:33–38.
53.
LuLL, LiuYJ, YangSG, ZhaoQJ, WangX, GongW, HanZB, XuZS, LuYX, et al. (2006). Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesis-supportive function and other potentials. Haematologica, 91:1017–1026.
54.
BarciaRN, SantosJM, FilipeM, TeixeiraM, MartinsJP, AlmeidaJ, Agua-DoceA, AlmeidaSC, VarelaA, et al. (2015). What makes umbilical cord tissue-derived mesenchymal stromal cells superior immunomodulators when compared to bone marrow derived mesenchymal stromal cells?. Stem Cells Int, 2015:583984.
55.
LiX, BaiJ, JiX, LiR, XuanY and WangY. (2014). Comprehensive characterization of four different populations of human mesenchymal stem cells as regards their immune properties, proliferation and differentiation. Int J Mol Med, 34:695–704.
56.
ProckopDJ, OhJY and LeeRH. (2017). Data against a common assumption: xenogeneic mouse models can be used to assay suppression of immunity by human MSCs. Mol Ther, 25:1748–1756.
57.
ProckopDJ and KeatingA. (2012). Relearning the lessons of genomic stability of human cells during expansion in culture: implications for clinical research. Stem Cells, 30:1051–1052.
58.
RenG, SuJ, ZhangL, ZhaoX, LingW, L'HuillieA, ZhangJ, LuY, RobertsAI, et al. (2009). Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression. Stem Cells, 27:1954–1962.
59.
LeeRH, YuJM, FoskettAM, PeltierG, ReneauJC, BazhanovN, OhJY and ProckopDJ. (2014). TSG-6 as a biomarker to predict efficacy of human mesenchymal stem/progenitor cells (hMSCs) in modulating sterile inflammation in vivo. Proc Natl Acad Sci U S A, 111:16766–16771.
60.
GrinnemoKH, ManssonA, DellgrenG, KlingbergD, WardellE, DrvotaV, TammikC, HolgerssonJ, RingdenO, SylvenC and Le BlancK. (2004). Xenoreactivity and engraftment of human mesenchymal stem cells transplanted into infarcted rat myocardium. J Thorac Cardiovasc Surg, 127:1293–1300.
61.
SchweitzerKS, JohnstoneBH, GarrisonJ, RushNI, CooperS, TraktuevDO, FengD, AdamowiczJJ, Van DemarkM, et al. (2011). Adipose stem cell treatment in mice attenuates lung and systemic injury induced by cigarette smoking. Am J Respir Crit Care Med, 183:215–225.
62.
HaoH, LiuJ, ShenJ, ZhaoY, LiuH, HouQ, TongC, TiD, DongL, et al. (2013). Multiple intravenous infusions of bone marrow mesenchymal stem cells reverse hyperglycemia in experimental type 2 diabetes rats. Biochem Biophys Res Commun, 436:418–423.
63.
KurtzbergJ, ProckopS, TeiraP, BittencourtH, LewisV, ChanKW, HornB, YuL, TalanoJA, et al. (2014). Allogeneic human mesenchymal stem cell therapy (remestemcel-L, Prochymal) as a rescue agent for severe refractory acute graft-versus-host disease in pediatric patients. Biol Blood Marrow Transplant, 20:229–235.
64.
FronteraWR and OchalaJ. (2015). Skeletal muscle: a brief review of structure and function. Calcif Tissue Int, 96:183–195.
65.
PedersenBK and FebbraioMA. (2008). Muscle as an endocrine organ: focus on muscle-derived interleukin-6. Physiol Rev, 88:1379–1406.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
